OCULAR ADNEXAL LYMPHOMAS: A CASE SERIES
(Abstract release date: 05/19/16)
EHA Library. Dhawan S. 06/09/16; 134782; PB1882
Dr. Saniya Dhawan
Contributions
Contributions
Abstract
Abstract: PB1882
Type: Publication Only
Background
Ocular lymphomas comprise only 1% of all non-Hodgkin lymphomas (NHL)1. However, it is a common extranodal site (5-15% of the extranodal cases)2. Lymphoma arises from the localized lymphoid tissue affecting the orbit, the eyelids, the conjunctiva and the lacrimal gland. The high curative potential of the local disease makes prompt diagnosis clinically important.
Aims
Case series involving 16 patients with ocular adnexal lymphoma and study of their treatment outcomes.
Methods
Retrospective review of 16 patients’ records from Royal Victoria Eye and Ear Hospital Dublin and University Hospital Waterford with a diagnosis of ocular adnexal lymphomas (OAL).
Results
In our case series, we found that follicular lymphomas were the most common subtype (50%), followed by extranodal marginal zone B-cell lymphoma or mucosa-associated lymphoid tissue (MALT) lymphoma (37.5%) and diffuse large B-cell lymphoma (12.5%). Majority of the patients were between the ages of 70-80 years. Male to female ratio was 1:1.3. Nine patients (56.2%) had primary OAL, 6(37.5%) had concurrent systemic involvement and one (6.25%) presented with ocular relapse of systemic disease. The most common presenting complaint was swelling of the eye or visible lump (62.5%) and the most common site was the orbit (37.5%) followed by conjunctiva (25%) and eyelid (25%).
Conclusion
Ocular site of the tumor does not influence the natural history of NHL. Localized disease was controlled in all cases. 10 patients (62.5%) had localized disease; radiotherapy remained the standard of treatment. Patients with localized disease who were treated with 4 cycles of monoclonal antiCD20 antibody (Rituximab) alone responded well to the treatment and sustained remission. Treatment with Rituximab alone averts potential toxicity of radiotherapy (e.g. cataract formation). Systemic disease accounted for 37.5% of the cases and were treated with systemic chemotherapy.References: 1. Fitzpatrick PJ, Macko S. Lymphoreticular tumors of the orbit. Int J Radiat Oncol Biol Phys. 1984; 10:333-340. 2. Lambo MJ, Brady LW, Shields CL. Lymphoid tumors of the orbit. In: Alberti WE, Sagerman RH, eds. Radiotherapy of Intraocular and Orbital Tumors. Berlin, Germany: Springer-Verlag. 1993; 205-216.
Session topic: E-poster
Keyword(s): Follicular lymphoma, MALT lymphoma, Non-Hodgkin's lymphoma
Type: Publication Only
Background
Ocular lymphomas comprise only 1% of all non-Hodgkin lymphomas (NHL)1. However, it is a common extranodal site (5-15% of the extranodal cases)2. Lymphoma arises from the localized lymphoid tissue affecting the orbit, the eyelids, the conjunctiva and the lacrimal gland. The high curative potential of the local disease makes prompt diagnosis clinically important.
Aims
Case series involving 16 patients with ocular adnexal lymphoma and study of their treatment outcomes.
Methods
Retrospective review of 16 patients’ records from Royal Victoria Eye and Ear Hospital Dublin and University Hospital Waterford with a diagnosis of ocular adnexal lymphomas (OAL).
Results
In our case series, we found that follicular lymphomas were the most common subtype (50%), followed by extranodal marginal zone B-cell lymphoma or mucosa-associated lymphoid tissue (MALT) lymphoma (37.5%) and diffuse large B-cell lymphoma (12.5%). Majority of the patients were between the ages of 70-80 years. Male to female ratio was 1:1.3. Nine patients (56.2%) had primary OAL, 6(37.5%) had concurrent systemic involvement and one (6.25%) presented with ocular relapse of systemic disease. The most common presenting complaint was swelling of the eye or visible lump (62.5%) and the most common site was the orbit (37.5%) followed by conjunctiva (25%) and eyelid (25%).
Conclusion
Ocular site of the tumor does not influence the natural history of NHL. Localized disease was controlled in all cases. 10 patients (62.5%) had localized disease; radiotherapy remained the standard of treatment. Patients with localized disease who were treated with 4 cycles of monoclonal antiCD20 antibody (Rituximab) alone responded well to the treatment and sustained remission. Treatment with Rituximab alone averts potential toxicity of radiotherapy (e.g. cataract formation). Systemic disease accounted for 37.5% of the cases and were treated with systemic chemotherapy.References: 1. Fitzpatrick PJ, Macko S. Lymphoreticular tumors of the orbit. Int J Radiat Oncol Biol Phys. 1984; 10:333-340. 2. Lambo MJ, Brady LW, Shields CL. Lymphoid tumors of the orbit. In: Alberti WE, Sagerman RH, eds. Radiotherapy of Intraocular and Orbital Tumors. Berlin, Germany: Springer-Verlag. 1993; 205-216.
Session topic: E-poster
Keyword(s): Follicular lymphoma, MALT lymphoma, Non-Hodgkin's lymphoma
Abstract: PB1882
Type: Publication Only
Background
Ocular lymphomas comprise only 1% of all non-Hodgkin lymphomas (NHL)1. However, it is a common extranodal site (5-15% of the extranodal cases)2. Lymphoma arises from the localized lymphoid tissue affecting the orbit, the eyelids, the conjunctiva and the lacrimal gland. The high curative potential of the local disease makes prompt diagnosis clinically important.
Aims
Case series involving 16 patients with ocular adnexal lymphoma and study of their treatment outcomes.
Methods
Retrospective review of 16 patients’ records from Royal Victoria Eye and Ear Hospital Dublin and University Hospital Waterford with a diagnosis of ocular adnexal lymphomas (OAL).
Results
In our case series, we found that follicular lymphomas were the most common subtype (50%), followed by extranodal marginal zone B-cell lymphoma or mucosa-associated lymphoid tissue (MALT) lymphoma (37.5%) and diffuse large B-cell lymphoma (12.5%). Majority of the patients were between the ages of 70-80 years. Male to female ratio was 1:1.3. Nine patients (56.2%) had primary OAL, 6(37.5%) had concurrent systemic involvement and one (6.25%) presented with ocular relapse of systemic disease. The most common presenting complaint was swelling of the eye or visible lump (62.5%) and the most common site was the orbit (37.5%) followed by conjunctiva (25%) and eyelid (25%).
Conclusion
Ocular site of the tumor does not influence the natural history of NHL. Localized disease was controlled in all cases. 10 patients (62.5%) had localized disease; radiotherapy remained the standard of treatment. Patients with localized disease who were treated with 4 cycles of monoclonal antiCD20 antibody (Rituximab) alone responded well to the treatment and sustained remission. Treatment with Rituximab alone averts potential toxicity of radiotherapy (e.g. cataract formation). Systemic disease accounted for 37.5% of the cases and were treated with systemic chemotherapy.References: 1. Fitzpatrick PJ, Macko S. Lymphoreticular tumors of the orbit. Int J Radiat Oncol Biol Phys. 1984; 10:333-340. 2. Lambo MJ, Brady LW, Shields CL. Lymphoid tumors of the orbit. In: Alberti WE, Sagerman RH, eds. Radiotherapy of Intraocular and Orbital Tumors. Berlin, Germany: Springer-Verlag. 1993; 205-216.
Session topic: E-poster
Keyword(s): Follicular lymphoma, MALT lymphoma, Non-Hodgkin's lymphoma
Type: Publication Only
Background
Ocular lymphomas comprise only 1% of all non-Hodgkin lymphomas (NHL)1. However, it is a common extranodal site (5-15% of the extranodal cases)2. Lymphoma arises from the localized lymphoid tissue affecting the orbit, the eyelids, the conjunctiva and the lacrimal gland. The high curative potential of the local disease makes prompt diagnosis clinically important.
Aims
Case series involving 16 patients with ocular adnexal lymphoma and study of their treatment outcomes.
Methods
Retrospective review of 16 patients’ records from Royal Victoria Eye and Ear Hospital Dublin and University Hospital Waterford with a diagnosis of ocular adnexal lymphomas (OAL).
Results
In our case series, we found that follicular lymphomas were the most common subtype (50%), followed by extranodal marginal zone B-cell lymphoma or mucosa-associated lymphoid tissue (MALT) lymphoma (37.5%) and diffuse large B-cell lymphoma (12.5%). Majority of the patients were between the ages of 70-80 years. Male to female ratio was 1:1.3. Nine patients (56.2%) had primary OAL, 6(37.5%) had concurrent systemic involvement and one (6.25%) presented with ocular relapse of systemic disease. The most common presenting complaint was swelling of the eye or visible lump (62.5%) and the most common site was the orbit (37.5%) followed by conjunctiva (25%) and eyelid (25%).
Conclusion
Ocular site of the tumor does not influence the natural history of NHL. Localized disease was controlled in all cases. 10 patients (62.5%) had localized disease; radiotherapy remained the standard of treatment. Patients with localized disease who were treated with 4 cycles of monoclonal antiCD20 antibody (Rituximab) alone responded well to the treatment and sustained remission. Treatment with Rituximab alone averts potential toxicity of radiotherapy (e.g. cataract formation). Systemic disease accounted for 37.5% of the cases and were treated with systemic chemotherapy.References: 1. Fitzpatrick PJ, Macko S. Lymphoreticular tumors of the orbit. Int J Radiat Oncol Biol Phys. 1984; 10:333-340. 2. Lambo MJ, Brady LW, Shields CL. Lymphoid tumors of the orbit. In: Alberti WE, Sagerman RH, eds. Radiotherapy of Intraocular and Orbital Tumors. Berlin, Germany: Springer-Verlag. 1993; 205-216.
Session topic: E-poster
Keyword(s): Follicular lymphoma, MALT lymphoma, Non-Hodgkin's lymphoma
{{ help_message }}
{{filter}}